Business
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial results for the periods ended August 31, 2025 and November 30th, respectively. All figures are reported in Canadian dollars. The Company’s full set of Audited Financial Stat
About this update from Pharmala Biotech Holdings, Inc.
[{"type":"image","alt":"PharmAla Biotech","displaySize":"","headline":null,"caption":"PharmAla Biotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rh7A3yGxrk9MQDPQWu1yYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866","width":300,"height":167}},"lazy":false},{"type":"text","content":"TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial results for the periods ended August 31, 2025 and November 30th, respectively. All figures are reported in Canadian dollars. The Company’s full set of Audited Financial Statements for the 2025 fiscal year, as well as its unaudited condensed interim consolidated financial statements for the first quarter of its 2026 fiscal year, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.","length":831,"tagName":"p"},{"type":"text","content":"“Commencing in late 2025 and continuing into Q1 2026 we have taken major steps towards the development of our novel molecules and look to continue this momentum throughout the remainder of fiscal 2026 with the goal of commencing our Phase 2a/b clinical trial in Australia,” said Nick Kadysh, CEO, PharmAla Biotech. “While we have been prioritizing our development, we have continued to see great traction in demand for our LaNeo™ MDMA, which has continued to grow our pipeline of clinical trial sales. With the approval of reimbursement for medical treatments using LaNeo MDMA in Australia, both by private medical insurers and by the Australian Department of Veterans Affairs (“DVA”), we believe that this trend will only continue.”","length":733,"tagName":"p"},{"type":"text","content":"Financial Highlights:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Customer deposits have continued to grow consistently:","lengt...